GlassScriptPhysician profile
Ronald Heine
NPI 1013912716
$4,448.72
in general payments reported to CMS, 2019-2025
33 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $540 · 2021: $1,084 · 2022: $613 · 2023: $630 · 2024: $643 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $848.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $550.78 | 2019-2025 | |
| Amgen INC. | $469.89 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbvie INC. | $441.47 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $329.47 | 2019-2025 | Gardasil 9, Rotateq, Enflonsia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.33 | 2020-2023 | Jardiance |
| Lilly USA, LLC | $178.35 | 2021-2024 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $169.01 | 2021-2024 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $151.00 | 2019-2021 | |
| Amarin Pharma, INC. | $131.29 | 2020-2021 | |
| Mylan Specialty L.P. | $123.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.44 | 2021-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $94.00 | 2019-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $80.41 | 2021-2022 | |
| Allergan, INC. | $55.51 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.84 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $40.72 | 2020-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Lundbeck LLC | $40.48 | 2022-2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $37.29 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $31.61 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.22 | 2022 | |
| Nevro Corp. | $25.36 | 2022 | |
| Corium, LLC | $24.89 | 2023 | Azstarys |
| Astellas Pharma US INC | $23.47 | 2024 | Veozah |
| Tactile Systems Technology INC | $23.21 | 2023 | Entre Plus, Flexitouch Plus |
| Medtronic, INC. | $23.01 | 2022 | |
| Cranial Technologies, INC | $21.27 | 2021 | |
| Insulet Corporation | $18.88 | 2024 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $15.78 | 2021 | |
| Shield Therapeutics INC | $15.77 | 2023 | Accrufer |
| Philips North America LLC | $14.94 | 2025 | Ecc Solutions |
| Phathom Pharmaceuticals, INC. | $14.89 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Heine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.